Abstract:BACKGROUND:Recent evidence has proven that long noncoding RNAs (lncRNAs) play important roles in cancer biology, while few lncRNAs have been characterized in NSCLC. Here, we characterized a novel lncRNA, SBF2 antisense RNA 1 (SBF2-AS1), in non-small cell lung cancer (NSCLC).METHODS:Quantitative real-time PCR was used to quantify SBF2-AS1 expression in NSCLC tissues and cell lines. The correlation of SBF2-AS1 expression with clinicopathologic features was analyzed in a cohort NSCLC patient. Loss of function and gain of function studies were performed to determine the effects of SBF2-AS1 on proliferation and metastasis of NSCLC cells. RNA immunoprecipitation and chromosome immunoprecipitation assay was performed to confirm the interaction between SBF2-AS1 with protein and chromosome.RESULTS:We confirmed that SBF2-AS1 was significantly upregulated in NSCLC compared with corresponding non-tumor tissues, and a high expression level of SBF2-AS1 was correlated with lymph node metastasis and advanced TNM stage. Using siRNAs specifically targeting SBF2-AS1 and plasmid vector, we successfully silenced and overexpressed SBF2-AS1 in NSCCLC cell lines and investigated its biological function both in vitro and in vivo. After the silencing of SBF2-AS1, the metastasis of NSCLC cells was significantly inhibited, the silencing of SBF2-AS1 decreased the proliferation of NSCLC cells, and the cell cycle was arrested at the G1 phase; while overexpression promoted proliferation ability. Xenograft tumor models revealed that the silencing of SBF2-AS1 inhibited tumor growth in vivo. We speculated that SBF2-AS1 might negatively regulate P21. RNA immunoprecipitation discovered that SBF2-AS2 could bind with a core component of polycomb repressive complex2, SUZ12. Additionally chromatin immunoprecipitation assay demonstrated that, after silencing SBF2-AS1, the enrichment of SUZ12 and trimethylation of histone 3 lysine 27 decreased at the promoter region of P21.CONCLUSIONS:We demonstrated that SBF2-AS1 is upregulated in NSCLC and promotes proliferation of NSCLC tumor cells. SBF2-AS1 may serve as a novel biomarker and potential therapeutic target for NSCLC patients.

Emerging Roles of a Pivotal Lncrna SBF2-AS1 in Cancers

LncRNA SBF2-AS1: A Budding Star in Various Cancers

The role of LncRNA LBX2-AS1 in cancers: functions, mechanisms and potential clinical utility

Promising Long Noncoding RNA DLX6-AS1 in Malignant Tumors

High Expression of Long Non-Coding RNA SBF2-AS1 Promotes Proliferation in Non-Small Cell Lung Cancer.

The Emerging Roles of LINC00665 in Human Cancers

Long Noncoding RNA: Its Partners and Their Roles in Cancer

The Role of Long Non-Coding RNF144A-AS1 in Cancer Progression

Biological functions and clinical significance of long noncoding RNAs in bladder cancer

A Promising New Cancer Marker: Long Noncoding RNA EGFR-AS1

Oncogenic Roles and Mechanisms of Lncrna AGAP2-AS1 in Human Solid Tumors.

Long Noncoding RNASBF2-AS1 Promotes Gastric Cancer Progression Via Regulating Mir-545/Ems1 Axis

Long Non-coding RNA ZFPM2-AS1: A Novel Biomarker in the Pathogenesis of Human Cancers

Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors.

Expression and Clinical Significance of Long Non-Coding RNA SBF2-AS1 in Non-Small Cell Lung Cancer

DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA

Oncogenic Roles of the Lncrna LINC00460 in Human Cancers

Long Noncoding RNA SBF2-AS1 is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma

LncRNA DARS-AS1 in human cancers: A comprehensive review of its potency as a biomarker and therapeutic target

The Emerging Roles of Long Noncoding RNAs As Hallmarks of Lung Cancer

Down-regulated lncRNA SBF2-AS1 inhibits tumorigenesis and progression of breast cancer by sponging microRNA-143 and repressing RRS1